These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24039090)

  • 21. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Regional Listing Increases Liver Transplant Rates for Those With Model for End-stage Liver Disease Score <15.
    Brown S; Savva Y; Barth R; LaMattina J; Thuluvath PJ
    Transplantation; 2020 Apr; 104(4):762-769. PubMed ID: 31568393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
    Ishaque T; Beckett J; Gentry S; Garonzik-Wang J; Karhadkar S; Lonze BE; Halazun KJ; Segev D; Massie AB
    Transplantation; 2024 Aug; 108(8):e170-e180. PubMed ID: 38548691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates.
    Braun HJ; Perito ER; Dodge JL; Rhee S; Roberts JP
    Am J Transplant; 2016 Nov; 16(11):3181-3191. PubMed ID: 27214757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Model for end-stage liver disease exceptions committee activity in Argentina: does it provide justice and equity among adult patients waiting for a liver transplant?
    McCormack L; Gadano A; Lendoire J; Quiñonez E; Imventarza O; Andriani O; Toselli L; Gil O; Gondolesi G; Bisigniano L; De Santibañes E
    HPB (Oxford); 2010 Oct; 12(8):531-7. PubMed ID: 20887320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional variations in peer reviewed liver allocation under the MELD system.
    Rodriguez-Luna H; Vargas HE; Moss A; Reddy KS; Freeman RB; Mulligan D
    Am J Transplant; 2005 Sep; 5(9):2244-7. PubMed ID: 16095504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Access to Liver Transplantation in Different ABO-Blood Groups and "Exceptions Points" in a Model for End-Stage Liver Disease Allocation System: A Brazilian Single-Center Study.
    Martino RB; Waisberg DR; Dias APM; Inoue VBS; Arantes RM; Haddad LBP; Rocha-Santos V; Pinheiro RSN; Nacif LS; D'Albuquerque LAC
    Transplant Proc; 2018 Apr; 50(3):754-757. PubMed ID: 29661430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Justifying Nonstandard Exception Requests for Pediatric Liver Transplant Candidates: An Analysis of Narratives Submitted to the United Network for Organ Sharing, 2009-2014.
    Perito ER; Braun HJ; Dodge JL; Rhee S; Roberts JP
    Am J Transplant; 2017 Aug; 17(8):2144-2154. PubMed ID: 28141916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.
    Francoz C; Belghiti J; Castaing D; Chazouillères O; Duclos-Vallée JC; Duvoux C; Lerut J; Le Treut YP; Moreau R; Mandot A; Pageaux G; Samuel D; Thabut D; Valla D; Durand F
    Liver Transpl; 2011 Oct; 17(10):1137-51. PubMed ID: 21695771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions.
    Bittermann T; Goldberg DS; Bauer CM; Khungar V
    Transplantation; 2017 May; 101(5):1099-1105. PubMed ID: 28121908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High model for end-stage liver disease score as a predictor of survival during long-term follow-up after liver transplantation.
    Suzuki H; Bartlett AS; Muiesan P; Jassem W; Rela M; Heaton N
    Transplant Proc; 2012 Mar; 44(2):384-8. PubMed ID: 22410023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MELD Exceptions and Rates of Waiting List Outcomes.
    Massie AB; Caffo B; Gentry SE; Hall EC; Axelrod DA; Lentine KL; Schnitzler MA; Gheorghian A; Salvalaggio PR; Segev DL
    Am J Transplant; 2011 Nov; 11(11):2362-71. PubMed ID: 21920019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era.
    Dutkowski P; Oberkofler CE; Slankamenac K; Puhan MA; Schadde E; Müllhaupt B; Geier A; Clavien PA
    Ann Surg; 2011 Nov; 254(5):745-53; discussion 753. PubMed ID: 22042468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional Social Vulnerability is Associated With Geographic Disparity in Waitlist Outcomes for Patients With Non-Hepatocellular Carcinoma Model for End-stage Liver Disease Exceptions in the United States.
    Cannon RM; Goldberg DS; Sheikh SS; Anderson DJ; Pozo M; Rabbani U; Locke JE
    Ann Surg; 2024 May; 279(5):825-831. PubMed ID: 37753656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY; Bass NM; Nikolai B; Merriman R; Davern TJ; Kerlan R; Ascher NL; Roberts JP
    Liver Transpl; 2003 Jul; 9(7):684-92. PubMed ID: 12827553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local access to subspecialty care influences the chance of receiving a liver transplant.
    Barritt AS; Telloni SA; Potter CW; Gerber DA; Hayashi PH
    Liver Transpl; 2013 Apr; 19(4):377-82. PubMed ID: 23213024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.